

## ADOLESCENT GYNECOLOGY: COMMON DISORDERS AND THEIR MANAGEMENT

ISSN (E): 2938-3765

Mirzajonova Yogutxon Nosirjon gizi Fergana Medical Institute of Public Health Assistant of the Department of Obstetrics and Gynecology

## **Abstract**

This review covers common gynecological disorders in adolescents, such as menstrual irregularities, dysmenorrhea, abnormal bleeding, and infections. Adolescence requires specialized care distinct from pediatric and adult gynecology, focusing on conservative treatment, patient education, and family involvement. Advances in hormonal therapy, minimally invasive diagnostics, and reproductive health education have improved outcomes. Providers must consider developmental stages, confidentiality, and cultural factors. This review offers evidence-based guidance for managing adolescent gynecological issues.

Keywords: Adolescent gynecology, menstrual disorders, dysmenorrhea, abnormal uterine bleeding, reproductive health, adolescent medicine.

## Introduction

Today's adolescent gynecology has emerged as a critical subspecialty within reproductive medicine, addressing the complex healthcare needs of young women during their formative reproductive years. The adolescent period, defined by the World Health Organization as spanning ages 10-19 years, represents a time of profound physiological, psychological, and social transformation that significantly influences gynecological health and well-being. During this developmental phase, the hypothalamic-pituitary-ovarian axis undergoes maturation, establishing cyclical hormonal patterns that govern reproductive function throughout a woman's life. The prevalence of gynecological disorders among adolescents has garnered increasing attention from healthcare professionals and researchers worldwide. Contemporary epidemiological studies indicate that approximately 75-90% of adolescent females experience some form of menstrualrelated concern during their teenage years, with dysmenorrhea affecting up to 95% of menstruating adolescents globally. These conditions not only impact physical health but also significantly affect academic performance, social interactions, and overall quality of life for young women. The unique characteristics of adolescent gynecological care necessitate specialized approaches that differ fundamentally from both pediatric and adult gynecological practice. Adolescent patients present with developing reproductive systems, incomplete pubertal maturation, and psychological vulnerability that require sensitive, age-appropriate medical interventions. Additionally, the complex interplay between biological development, social pressures, and emerging sexuality creates a healthcare environment that demands exceptional clinical expertise and communication skills.





Modern approaches to adolescent gynecological care emphasize comprehensive, patient-centered strategies that incorporate evidence-based medicine with developmental considerations. The integration of family involvement, peer support systems, and educational interventions has proven essential for successful treatment outcomes. Furthermore, advances in diagnostic technologies, pharmacological treatments, and minimally invasive procedures have expanded therapeutic options while maintaining the conservative approach traditionally favored in adolescent populations. Healthcare disparities and access barriers continue to challenge optimal adolescent gynecological care delivery. Socioeconomic factors, cultural beliefs, geographic limitations, and healthcare system constraints often prevent timely diagnosis and appropriate treatment of gynecological conditions in adolescent populations. Addressing these challenges requires coordinated efforts among healthcare providers, educational institutions, public health officials, and community organizations to ensure equitable access to specialized care.

Dysmenorrhea represents one of the most prevalent gynecological complaints among adolescents, with primary dysmenorrhea affecting 60-93% of menstruating adolescents according to recent epidemiological studies. Primary dysmenorrhea, characterized by cramping pelvic pain occurring with menstruation in the absence of identifiable pelvic pathology, typically begins within one to two years after menarche as ovulatory cycles become established. The pathophysiology involves excessive production of prostaglandins, particularly prostaglandin F2α and prostaglandin E2, which cause intense uterine contractions, vasoconstriction, and sensitization of pain receptors. The clinical presentation of primary dysmenorrhea includes cramping lower abdominal pain that may radiate to the lower back and thighs, typically beginning shortly before or with the onset of menstrual flow and lasting one to three days. Associated symptoms frequently include nausea, vomiting, diarrhea, headache, and fatigue, which can significantly impact academic performance, physical activities, and social functioning. Studies indicate that dysmenorrhea causes school absenteeism in 14-52% of affected adolescents, highlighting the substantial impact on educational outcomes and quality of life. Secondary dysmenorrhea, caused by underlying pelvic pathology such as endometriosis, adenomyosis, or structural abnormalities, occurs less frequently in adolescents but requires careful consideration, particularly when pain begins more than two years after menarche or fails to respond to appropriate medical therapy. Endometriosis affects an estimated 25-38% of adolescents with chronic pelvic pain and up to 75% of those with severe dysmenorrhea that does not respond to conventional treatment. Early recognition and diagnosis of endometriosis in adolescents is crucial for preventing long-term complications and preserving reproductive function. The diagnostic evaluation of dysmenorrhea begins with comprehensive history-taking to characterize pain patterns, associated symptoms, and impact on daily activities. Physical examination, including pelvic examination when appropriate and clinically indicated, helps exclude anatomical abnormalities and signs of secondary causes. The decision to perform pelvic examination in adolescents requires careful consideration of medical necessity, patient comfort, and psychological readiness, with alternatives such as transabdominal or transrectal ultrasound considered when imaging is required. Treatment of primary dysmenorrhea follows a stepwise approach beginning with nonsteroidal anti-inflammatory drugs, which represent first-line therapy due to their dual action of reducing prostaglandin synthesis and providing analgesic effects. Ibuprofen, naproxen, and mefenamic acid have demonstrated superior efficacy compared





to acetaminophen in multiple randomized controlled trials. Optimal dosing involves initiating treatment one to two days before expected menstrual onset and continuing regularly throughout the first few days of menstruation rather than using as-needed dosing strategies.

ISSN (E): 2938-3765

Hormonal therapies serve as second-line treatment for adolescents with dysmenorrhea that does not respond adequately to nonsteroidal anti-inflammatory drugs. Combined oral contraceptive pills effectively reduce dysmenorrhea severity in 70-80% of users through suppression of ovulation and reduction of prostaglandin production. Extended-cycle or continuous hormonal regimens may provide additional benefits for adolescents with severe symptoms by reducing the frequency of menstrual periods. Alternative hormonal options include the contraceptive patch, vaginal ring, and progestin-releasing intrauterine devices, each offering unique advantages for specific patient populations. Complementary and alternative therapies have gained increasing acceptance as adjunctive treatments for adolescent dysmenorrhea. Heat therapy, including heating pads and warm baths, provides safe and effective symptom relief through muscle relaxation and improved blood flow. Regular aerobic exercise has demonstrated significant benefits in reducing dysmenorrhea severity and improving overall well-being. Dietary modifications, including omega-3 fatty acid supplementation, magnesium, and vitamin B1, have shown promise in some studies, though evidence remains limited compared to conventional therapies.

Abnormal uterine bleeding represents a significant clinical concern in adolescent gynecology, encompassing various patterns of menstrual bleeding that deviate from normal parameters of frequency, duration, volume, or regularity. The International Federation of Gynecology and Obstetrics classification system provides standardized terminology for describing abnormal uterine bleeding patterns, facilitating consistent communication among healthcare providers and improving clinical care quality. Heavy menstrual bleeding, defined as excessive menstrual blood loss that interferes with a woman's physical, emotional, social, and material quality of life, affects approximately 20-25% of adolescents during their reproductive years. Objective measurement of menstrual blood loss remains challenging in clinical practice, with subjective assessment tools such as the Pictorial Blood Loss Assessment Chart providing practical alternatives for quantifying bleeding severity. Adolescents with heavy menstrual bleeding often report changing sanitary products every hour, bleeding for more than seven days, or experiencing flooding and clotting that disrupts normal activities. The etiology of abnormal uterine bleeding in adolescents differs significantly from adult populations, with anovulation accounting for the majority of cases during the first two years following menarche. The immature hypothalamic-pituitary-ovarian axis requires time to establish regular ovulatory cycles, resulting in irregular bleeding patterns that may include prolonged cycles, heavy bleeding, or unpredictable timing. Structural causes of abnormal uterine bleeding, such as leiomyomas or polyps, occur less frequently in adolescents but require consideration in cases of persistent or severe symptoms.

Bleeding disorders represent an important but often overlooked cause of heavy menstrual bleeding in adolescents, with studies indicating that 5-36% of adolescents presenting with heavy menstrual bleeding have underlying coagulation abnormalities. Von Willebrand disease, the most common inherited bleeding disorder, affects approximately 1% of the population and may first manifest as heavy menstrual bleeding during adolescence. Platelet function disorders, factor deficiencies, and other coagulopathies can similarly present with gynecological bleeding and require specialized



hematological evaluation. The diagnostic evaluation of abnormal uterine bleeding in adolescents requires systematic assessment to identify underlying causes and guide appropriate treatment strategies. Laboratory investigations should include complete blood count to assess for anemia, comprehensive metabolic panel, thyroid function tests, and coagulation studies when bleeding disorders are suspected. Pregnancy testing remains essential for all sexually active adolescents, while hormonal assessments may be indicated based on clinical presentation and suspected underlying conditions. Imaging studies play an important role in the evaluation of abnormal uterine bleeding when structural abnormalities are suspected or when conservative management fails to provide adequate symptom control. Transabdominal pelvic ultrasound represents the initial imaging modality of choice, providing valuable information about uterine size, endometrial thickness, and ovarian morphology while avoiding the discomfort associated with transvaginal approaches in adolescent patients. Magnetic resonance imaging may be indicated for further characterization of structural abnormalities or when ultrasound findings are inconclusive. Medical management of abnormal uterine bleeding in adolescents emphasizes hormonal therapies that provide effective symptom control while supporting normal pubertal development and bone health. Combined oral contraceptive pills represent first-line therapy for most adolescents with abnormal uterine bleeding, offering excellent cycle control, reduction in menstrual blood loss, and additional non-contraceptive benefits including decreased risk of ovarian and endometrial cancers. Extended-cycle formulations may provide particular advantages for adolescents with severe symptoms by reducing the frequency of withdrawal bleeding.

Progestin-only therapies offer alternative options for adolescents with contraindications to estrogen-containing medications or specific clinical indications. Oral progestins such as medroxyprogesterone acetate or norethindrone acetate can be used cyclically to induce withdrawal bleeding or continuously for endometrial suppression. The levonorgestrel-releasing intrauterine device represents an effective long-term option for appropriately selected adolescents, providing significant reduction in menstrual blood loss and high contraceptive efficacy. Acute management of severe bleeding episodes may require intensive hormonal therapy to achieve rapid hemostasis and prevent further blood loss. High-dose estrogen therapy, administered intravenously or orally, can provide rapid endometrial proliferation and bleeding control in emergency situations. Combination estrogen-progestin regimens may be used for less severe acute bleeding, with subsequent transition to maintenance hormonal therapy for long-term management.

Infectious conditions affecting the female reproductive tract represent significant health concerns in adolescent populations, with sexually transmitted infections constituting a major component of gynecological morbidity in this age group. Adolescents aged 15-24 years account for approximately half of all new sexually transmitted infection cases in the United States, despite representing only 25% of the sexually active population. This disproportionate burden reflects biological, behavioral, and social factors that increase adolescent susceptibility to reproductive tract infections. Bacterial vaginosis represents the most common cause of vaginal discharge in reproductive-aged women, affecting approximately 15-20% of adolescents. The condition results from disruption of normal vaginal flora, with decreased lactobacilli and overgrowth of anaerobic bacteria including Gardnerella vaginalis, Prevotella species, and Mobiluncus species. Clinical presentation includes characteristic malodorous vaginal discharge, vaginal pH greater than 4.5,





and positive amine test, though many cases remain asymptomatic. Treatment involves oral or topical metronidazole or clindamycin, with consideration of partner treatment in recurrent cases. Vulvovaginal candidiasis affects approximately 75% of women during their lifetime, with peak incidence occurring during the reproductive years. Candida albicans accounts for 85-90% of cases, while non-albicans species including Candida glabrata and Candida tropicalis cause remaining infections and may demonstrate resistance to conventional antifungal therapies. Risk factors in adolescents include antibiotic use, hormonal contraceptive use, diabetes mellitus, and immunocompromised states. Clinical presentation includes vulvar pruritus, external dysuria, and characteristic cottage cheese-like vaginal discharge.

Contraceptive counseling and provision represent essential components of comprehensive adolescent gynecological care, requiring specialized approaches that address the unique needs, concerns, and circumstances of teenage patients. Adolescent sexuality and reproductive behavior patterns demonstrate significant individual variation, necessitating personalized contraceptive counseling that considers medical eligibility, lifestyle factors, relationship dynamics, and personal preferences. Healthcare providers must navigate complex issues including confidentiality requirements, parental involvement considerations, and legal frameworks while prioritizing adolescent health and autonomy. Combined oral contraceptive pills remain among the most popular contraceptive methods for adolescents, providing highly effective pregnancy prevention when used consistently and correctly. Modern low-dose formulations demonstrate excellent safety profiles in healthy adolescents, with non-contraceptive benefits including improved menstrual cycle control, reduced dysmenorrhea, decreased acne severity, and potential protection against ovarian and endometrial cancers. Extended-cycle or continuous regimens may offer particular advantages for adolescents seeking reduced menstrual frequency or management of menstrualrelated symptoms. Long-acting reversible contraceptive methods, including intrauterine devices and subdermal implants, have gained increasing acceptance for adolescent populations due to their superior effectiveness, convenience, and reversibility. The American College of Obstetricians and Gynecologists and the American Academy of Pediatrics recommend long-acting reversible contraceptives as first-line options for sexually active adolescents seeking highly effective contraception. These methods eliminate user-dependent factors that contribute to typical-use failure rates with other contraceptive options. The levonorgestrel-releasing intrauterine device provides highly effective contraception with additional benefits including significant reduction in menstrual blood loss, making it particularly suitable for adolescents with heavy menstrual bleeding or anemia. Insertion procedures in adolescents require careful patient selection, appropriate preprocedure counseling, and consideration of comfort measures including local anesthesia or oral analgesics. Contrary to historical concerns, intrauterine device use does not increase pelvic inflammatory disease risk in appropriately screened adolescents.

The healthcare environment significantly influences adolescent comfort and willingness to engage in medical care. Private, comfortable settings that respect adolescent dignity and autonomy facilitate open communication and information sharing. Visual materials, educational resources, and technology-based tools can enhance understanding and engagement while appealing to adolescent learning preferences. Healthcare providers should consider offering separate consultations with adolescents apart from parents or guardians to discuss sensitive topics and



ensure confidential communication opportunities. Cultural competency represents an essential component of adolescent gynecological care, requiring understanding of diverse cultural backgrounds, religious beliefs, and family dynamics that influence health behaviors and treatment acceptance. Healthcare providers must recognize and respect cultural variations in attitudes toward sexuality, gender roles, family involvement in healthcare decisions, and medical interventions while maintaining commitment to evidence-based care and adolescent well-being. Mental health considerations play crucial roles in adolescent gynecological care, with high rates of depression, anxiety, and other psychological conditions affecting this population. Reproductive health concerns may exacerbate existing mental health challenges or contribute to new psychological symptoms through impacts on body image, self-esteem, and social functioning. Healthcare providers should maintain awareness of mental health screening opportunities and referral resources while recognizing the interconnections between physical and psychological well-being. In conclusion, adolescent gynecology requires specialized knowledge of developmental physiology, evidence-based treatments, and sensitive communication tailored to young women's unique needs. Management focuses on conservative therapies that relieve symptoms, support normal development, and prevent complications. Advances in hormonal treatments and minimally invasive techniques have expanded safe options for this population. High-quality, accessible care addressing both medical and psychosocial aspects is vital. Providers must be skilled in adolescentspecific communication, confidentiality, and family dynamics. Preventive care, education, and early intervention are key to promoting reproductive health.

ISSN (E): 2938-3765

Future directions include research on treatments, new diagnostic tools, comprehensive health education, and healthcare system improvements to reduce disparities. Collaboration among providers, educators, families, and communities is essential to support adolescent reproductive health globally.

## **References:**

- Umarovich, B. M. (2025). DEVELOPING OF VIRAL INFECTIONS IN HEMATOPOIETIC STEM-CELL TRANSPLANT (HSCT) RECIPIENTS. Web of Medicine: Journal of Medicine, Practice and Nursing, 3(5), 468-473.
- Muhammadiev, S. (2025). HEMIEPIPHYSIODESIS IN PEDIATRIC ORTHOPAEDICS AS A TREATMENT OF KNEE DEFORMITIES. International Journal of Artificial Intelligence, 1(4), 225-227.
- 3. Pulatjonovna, U. M. (2024). METABOLITE SYNDROME AND **COGNITIVE** IMPAIRMENT. IMRAS, 7(6), 419-423.
- Умарова, М., & Кодиржонов, Н. (2022). ТРОМБОЛИТИЧЕСКАЯ ТЕРАПИЯ В ЛЕЧЕНИИ ИШЕМИЧЕСКОГО ИНСУЛЬТА. Theoretical aspects in the formation of pedagogical sciences, 1(5), 218-220.
- 5. Умарова, M. (2021).МИГРЕН КАСАЛЛИГИ BA УНИНГ ШОШИЛИНЧ ТЕРАПИЯСИНИ ТАКОМИЛЛАШТИРИШ. ИНТЕРНАУКА, 47, 93.
- Хошимова, А. Ё. (2018). ВЛИЯНИЕ ЗАГРЯЗНЕНИЯ ОКРУЖАЮЩЕЙ СРЕДЫ НА АСТМОЙ. ЗАБОЛЕВАЕМОСТЬ БРОНХИАЛЬНОЙ Актуальные вопросы современной пульмонологии. Ма, 200.



АБДУГАНИЕВА, А. Ё., & ЮЛДАШЕВА, Х. Б. К. ЛАБОРАТОРНАЯ ДИАГНОСТИКА COVID-19. ИНТЕРНАУКА Общество Учредители: ответственностью" Интернаука", 37-38.

ISSN (E): 2938-3765

- 8. Умарова, М. (2021). ИНСОМНИА ВА МЕТАБОЛИК СИНДРОМНИНГ ЎЗАРО КОМОРБИДЛИГИ МУАММОНИНГ ДОЛЗАРБЛИГИ. Интернаука, (20-7), 29-30.
- 9. Исмаилов, C. И., & Маматханова, Γ. M. (2022).ЭЛЕКТРОННЫЙ ВАЖНЕЙШИЙ **ДОКУМЕНТООБОРОТ** КАК ФАКТОР ПОВЫШЕНИЯ ЭФФЕКТИВНОСТИ УПРАВЛЕНИЯ ЗДРАВООХРАНЕНИЕМ. Евразийский журнал медицинских и естественных наук, 2(8), 38-45.
- 10. Erkinovich, M. B. (2023). Prevention and Modern Treatment of Fatty Embolism in Traumatological Patients. Eurasian Medical Research Periodical, 21, 158-164.
- 11. Abdujabborova, C. (2024). O'tkir zaharliligini aniqlash" LUPINUS AS". Universal xalqaro ilmiy jurnal, 1(9), 151-157.
- 12. Abdujabborova, C. (2024). PSORALEA DRUPACEAE **BUNGE** KOSTYANKOVA OR AKKURAI) CHEMICAL COMPOSITION AND APPLICATION IN MEDICINE. B INTERNATIONAL BULLETIN OF MEDICAL SCIENCES AND CLINICAL RESEARCH (Т. 4, Выпуск 1, сс. 9–14). Zenodo.
- 13. Erkinovich, M. B. (2025, February). ACCUMULATION OF FLUID IN THE KNEE JOINT. In The Conference Hub (pp. 31-35).
- 14. Erkinovich, M. B. (2025). EFFECT OF JOINT FLUID ON JOINT ACTIVITY IN THE BODY. Web of Medicine: Journal of Medicine, Practice and Nursing, 3(2), 256-260.
- 15. Maxmudovna, M. G., Qizi, S. M. I., & Xasanboyevich, X. S. (2024). VIRAL HEPATITIS DISEASE AND ITS SPREAD AMONG THE POPULATION. THE EXAMPLE OF RISHTAN DISTRICT. Eurasian Journal of Medical and Natural Sciences, 4(1-2), 118-121.
- 16. Mamatkhanova, G. M., & Ismailov, S. I. (2021). Optimization Of Medical Records And Implementation Of Electronic Systems In Healthcare. The American Journal of Medical Sciences and Pharmaceutical Research, 3(01), 193-198.
- 17. Маматханова,  $\Gamma$ . (2021). Оптимизация медицинской учетной документации и внедрение электронных систем в здравоохранение. Общество и инновации, 2(8/S), 61-67.
- 18. Мурадимова, А. Р. (2019). Нейрофизиологический аспект метаболической терапии хронической церебральной ишемии. In Инновации в медицине. Материалы I международной научно-практической конференции-Махачкала, 2019.-Том. II.-232 с. (р. 192).
- 19. Lutfidin o'g'li, Y. B. (2025). ENDEMIK BUQOQ KASALLIGINI TA'SIRIDAN YO'LDOSH **TERMINAL** SO'RGICHLARDAGI **QON TOMIRLARNING** PATOMORFOLOGIK O'ZGARISHLARI. THEORY AND ANALYTICAL ASPECTS OF RECENT RESEARCH, 3(33), 322-325.
- 20. Lutfidin o'g'li, Y. B. (2025). Major Hystologic Types of Lung Cancer. Miasto Przyszłości, 57, 81-86.
- 21. Yusupov, B., & Xatamova, M. (2025). GIPERTIREOZ TA'SIRIDAN YO'LDOSH TERMINAL SO'RG'ICHLARDAGI QON TOMIRLARNING PATOMORFOLOGIK O'ZGARISHLARI. Modern Science and Research, 4(2), 432-437.



ISSN (E): 2938-3765





- 22. Habibullayevna, A. G., & Shavkatjon o'g'li, Q. S. (2025, February). STRUCTURE AND INTRACELLULAR ACTIVITY OF THE DNA-CONTAINING HERPES SIMPLEX VIRUS. In International Educators Conference (pp. 126-132).
- 23. Мурадимова, А. Р. (2019). КЛИНИКО-НЕВРОЛОГИЧЕСКИЕ ОСОБЕННОСТИ ТЕЧЕНИЯ СО-СУДИСТОЙ ЭПИЛЕПСИИ, ПРОГНОЗИРОВАНИЯ И ЛЕЧЕНИЯ. In Инновации в медицине. Материалы І международной научно-практической конференции-Махачкала, 2019.-Том. II.-232 с. (р. 178).
- 24. Мурадимова, А. Р. (2019). КЛИНИКО-ДИАГНОСТИЧЕСКИЕ АСПЕКТЫ И СОВРЕМЕННЫЕ ПОДХОДЫ К ЛЕЧЕНИЮ СОСУДИСТОЙ ДЕМЕНЦИИ. In Инновации в медицине. Материалы I международной научно-практической конференции-Махачкала, 2019.-Том. II.-232 с. (р. 185).
- 25. Xojiakbarovna, K. M. (2025). SKLETAL MUSCLE RELAXANTS. PERIPHERALLY ACTING SKLETAL MUSCLE RELAXAXANTS: NEUROMUSCULAR BLOCKERS AND SYNTHETIC COMPETITIVE BLOCKERS. Web of Medicine: Journal of Medicine, Practice and Nursing, 3(5), 509-514.
- 26. Yevgenevna, S. O. (2025). PREDICTION OF PREECLAMPSIA DEVELOPMENT IN PREGNANT WOMEN WITH OVERWEIGHT AND OBESITY. Web of Medicine: Journal of Medicine, Practice and Nursing, 3(5), 561-568.
- 27. Isroilova, G. (2023). DEVELOPING THE PRINCIPLES OF STUDYING AND TREATMENT OF VAGINAL DYSBIOSIS DURING PREGNANCY. Modern Science and Research, 2(4), 52-53.
- 28. Юсупова, Р. Т., & Шаланкова, О. Е. (2020). РЕПРОДУКТИВНОЕ ЗДОРОВЬЕ ДЕВОЧЕК-ПОДРОСТКОВ, ПРОЖИВАЮЩИХ В УСЛОВИЯХ ФЕРГАНСКОЙ ДОЛИНЫ. Іп Университетская наука: взгляд в будущее (рр. 612-614).
- 29. Пулатова, Н. С., Йигиталиев, А. Б., & Абдурашидов, А. А. ЭПИДЕМИОЛОГИЯ РАКА ТЕЛА МАТКИ В ФЕРГАНСКОЙ ОБЛАСТИ. 1-SON, 1-JILD IYUL 2022 1-QISM, 29.
- 30. Эгамбердиев, Д. Э., Абдурашидов, А. А., & Эргашов, У. Ш. ПРОФИЛАКТИКА И МЕТОФИЛАКТИКА МОЧЕКАМЕННОЙ БОЛЕЗНИ.
- 31. Husanboy, U. (2024). ACUTE HEMORRHAGIC CYSTITIS DISEASE IN CHILDREN AND ITS DEVELOPMENT IN THE CHILD'S DODY. In International Conference on Multidisciplinary Sciences and Educational Practices (pp. 88-94).
- 32. Умарова, М. (2021). ИНСУЛТДАН КЕЙИНГИ ТАЛВАСА СИНДРОМИ. Интернаука, (18-5), 46-48.
- 33. Pattoyevich, G. A. (2025). IRON DEFICIENCY ANEMIA IN CHILDREN: EARLY DIAGNOSIS AND MODERN TREATMENT APPROACHES. Web of Medicine: Journal of Medicine, Practice and Nursing, 3(5), 494-501.
- 34. Ravshanovna, R. Y., & Abduxoliq o'g'li, R. A. (2024). Clinical and Morphological Characteristics and Treatment of Gaucher Disease. Miasto Przyszłości, 49, 1407-1412.

